PMID-37709824 – Anamorelin Cancer Cachexia Meta-Analysis
Taniguchi J et al. "Anamorelin for cancer cachexia: a systematic review and meta-analysis," Scientific Reports, 2023;13:15542. doi:10.1038/s41598-023-42446-x
Quick Reference
| Property | Value |
|---|---|
| PMID | 37709824 |
| DOI | 10.1038/s41598-023-42446-x |
| Year | 2023 |
| Journal | Scientific Reports |
| Study Type | Systematic Review + Meta-Analysis |
| Evidence Level | I |
| Sample | 1,944 patients across 7 RCTs |
| Peptide(s) Studied | Anamorelin (ghrelin receptor agonist, ghrelin axis peptide) |
Key Findings
- Systematic review and meta-analysis pooling 7 RCTs with 1,944 cancer cachexia patients treated with anamorelin
- Anamorelin significantly increased body weight: weighted mean difference +1.73 kg vs placebo (p<0.001)
- Lean body mass significantly increased: weighted mean difference +1.06 kg vs placebo (p<0.001)
- Appetite scores (FAACT-A/CS) significantly improved with anamorelin
- Handgrip strength was NOT significantly improved in the pooled analysis, confirming the ROMANA trial findings
- The treatment was well tolerated with low rates of serious adverse events across all included trials
- Subgroup analyses suggested the weight gain effect was consistent across cancer types (lung, GI, pancreatic)
Study Design
Systematic review and meta-analysis following PRISMA guidelines. Searched PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov for RCTs of anamorelin in cancer cachexia. Seven RCTs met inclusion criteria. Random-effects meta-analysis performed for body weight, lean body mass, handgrip strength, appetite, and safety endpoints.
Limitations
- Heterogeneity in cancer types, stages, and concurrent treatments across included trials
- Most included trials were 12 weeks in duration — long-term effects unknown
- The pooled analysis inherits the limitation that body weight/LBM changes did not translate to functional improvement
- Publication bias not fully excluded despite funnel plot analysis
- No survival data pooled — unable to assess mortality benefit
Clinical Relevance
This meta-analysis provides Level I evidence confirming that anamorelin produces statistically significant and clinically meaningful body weight (+1.73 kg) and lean body mass (+1.06 kg) gains in cancer cachexia. However, the persistent failure to improve grip strength raises fundamental questions about whether the anabolic effect translates to meaningful functional recovery. For practitioners, this supports anamorelin as a body composition intervention but highlights the need for multimodal cachexia management combining pharmacotherapy with nutritional and exercise interventions.
Related
#research #meta-analysis #evidence-level-I #cancer